RxDoctor Payments Data

Prakash Amin, MD

Psychiatry · Mercerville, NJNPI 1750452744

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $13,150 of the $14,647 with a category attached, or 89.8%. AbbVie accounts for 93.4% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $4,993 and has fallen 94.2% since, to $289 in 2025. Among psychiatry clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,647in general payments, 2019–2025

Across 129 payments — averaging $113.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$14K
  • Otsuka America Pharmaceutical, Inc.$233
  • Lundbeck LLC$231
  • Axsome Therapeutics, Inc.$170
  • Sunovion Pharmaceuticals Inc.$166
  • Takeda Pharmaceuticals U.S.A., Inc.$80
  • plus $82 from 2 others

What the payments were for

  • Speaking & faculty fees$13,15090%
  • Food & beverage$1,49710%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,647 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in New Jersey.

See all psychiatry providers in New Jersey

Medicare billing

Part B allowed, 2024
$56,904
Medicare patients
128
Services billed
545

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide78$69,373
VraylarCariprazine Hcl42$51,272
FanaptIloperidone12$23,358
BelsomraSuvorexant30$12,548
Duloxetine Hcl153$5,345
Divalproex Sodium ErDivalproex Sodium39$4,891
Buspirone Hcl210$4,334
Venlafaxine Hcl ErVenlafaxine Hcl85$3,602
Vilazodone Hcl22$3,225
Bupropion XlBupropion Hcl85$3,040
Escitalopram Oxalate189$3,033
Aripiprazole61$3,028
Oxcarbazepine48$2,521
Alprazolam384$2,294
Sertraline Hcl174$2,261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$80$69,37378 claims
AbbVieVraylar$13,685$51,27242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in New Jersey.

Other psychiatry in Mercerville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →